

1 **Molecular and serological investigation of the 2021 COVID-19 case surge in**  
2 **Mongolian vaccinees**

3 Naranjargal J. Dashdorj; *PhD*<sup>1</sup>, Naranbaatar D. Dashdorj; *PhD*<sup>1#</sup>, Mitali Mishra; *PhD*<sup>2</sup>,  
4 Lisa Danzig; *MD*<sup>3</sup>, Thomas Briese; *PhD*<sup>2</sup>, W. Ian Lipkin; *MD*<sup>2#</sup>§, Nischay Mishra; *PhD*<sup>2#</sup>§

5  
6 <sup>1</sup> Onom Foundation, Ulaanbaatar, Mongolia

7 <sup>2</sup> Center for Infection and Immunity, Columbia University, New York, USA

8 <sup>3</sup> PANDEFENSE Advisory, USA

9  
10 #corresponding authors

11 §NM and WIL equally contributed

12  
13 Corresponding author (s)

14 Nischay Mishra, PhD , email: [nm2641@cumc.columbia.edu](mailto:nm2641@cumc.columbia.edu)

15 W. Ian Lipkin, MD, email: [wil2001@cumc.columbia.edu](mailto:wil2001@cumc.columbia.edu)

16 Naranbaatar D. Dashdorj, PhD, email: [nd@onomfoundation.org](mailto:nd@onomfoundation.org)

17  
18  
19 Word count: 591

20 Table: 1

21 Figure: 1

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

## 46 **Abstract**

47 A surge in Covid-19 cases in Mongolia in March 2021 resulted in a government-  
48 mandated shutdown. This shutdown was relaxed in May 2021 as case numbers  
49 decreased and nationwide vaccination rates using Sinopharm, Covishield/AstraZeneca,  
50 Sputnik V, and Pfizer/BioNTech vaccines exceeded 50% of the population. Case rates  
51 increased again in early June 2021 in both vaccinated and non-vaccinated individuals.  
52 To determine whether the surge was due to the emergence of Delta or another variant,  
53 or vaccine failure, a rapid, opportunistic investigation was conducted that comprised  
54 virus sequence analysis of nasal swab samples from breakthrough cases and antibody  
55 assays of plasma from healthy vaccinees. More than 90% of breakthrough infections  
56 during the second case surge were due to the Alpha variant. Spike protein ELISA and  
57 SARS-CoV-2 neutralization assays data revealed large differences in plasma titers of  
58 antibodies to SARS-CoV-2, with mRNA vaccines eliciting higher titers than adenovirus-  
59 vectored or killed virus vaccines.

60

## 61 **Introduction**

62 In March 2021 an increase in COVID-19 cases in Mongolia (population 3.3 million) led  
63 to a government-mandated shutdown and a nationwide vaccination program with four  
64 different vaccines. In early June, a reduction in cases attributed to vaccination led to  
65 relaxation of the shutdown that was followed by a surge in disease (Figure. 1).

66

67 To determine whether the surge was due to the emergence of Delta or another variant,  
68 or vaccine failure, a rapid, opportunistic investigation was conducted that comprised  
69 virus sequence analysis of nasal swab samples from breakthrough cases and antibody  
70 assays of plasma from healthy vaccinees.

71

## 72 **Methods**

73 Samples were collected with informed consent. RNA from nasal swabs was extracted  
74 for Illumina sequencing using the Mybaits capture system (Arbor Biosciences). Reads  
75 were mapped and aligned to SARS-CoV-2 reference sequence (accession no.  
76 NC\_045512) and variant analyses performed using GISAID, NextClade[1]. Plasma from  
77 healthy vaccinees were screened for anti-SARS-CoV-2 antibodies in EUROIMMUN  
78 Anti-SARS-CoV-2 IgG ELISA and EUROIMMUN Anti-SARS-CoV-2 NCP IgG ELISA.  
79 Neutralizing antibodies (NAb) to Washington, and Delta SARS-CoV-2 variants were  
80 quantitated in an absolute end point neutralization assay that measures 100%  
81 neutralizing activity with a SARS-CoV-2 qPCR [2].

82

## 83 **Results**

84 We sequenced 97 nasal samples from Covid-19 patients with breakthrough infections  
85 after vaccination (Supplementary Table 1), and tested plasma from 100 healthy subjects  
86 for antibodies to SARS-CoV-2 (surface glycoprotein, S and nucleocapsid  
87 phosphoprotein, NCP), and NAb after Covishield/AstraZeneca, Sputnik V, Sinopharm,  
88 or Pfizer/BioNTech vaccination (Table 1).

89 Full-length SARS-CoV-2 sequences were obtained from 92 samples. Eighty-seven of  
90 92 (94.6%) were Alpha variant. Five of 92 (5.4%) were Delta variant. Of 87 Alpha  
91 variant breakthrough infections, 54 (62.1 %) were from Sinopharm, 7 (8.0%) from

92 Sputnik V, 23 (26.4%) from Covishield/AZN, and 3 (3.4%) from Pfizer/BioNTech  
93 vaccinees. Of 5 breakthrough Delta variant infections, 1 (20%) was from Sinopharm, 3  
94 (60%) were from Covishield/AZN, and 1 (20%) was from Pfizer/BioNTech vaccinees  
95 (Supplementary Table 1).

96 More subjects had spike ELISA reactivity after Pfizer/BioNTech (91.6%), and  
97 Covishield/AstraZeneca (70.8%), than Sputnik V (29.2%) or Sinopharm (12.5%).  
98 Nucleoprotein reactivity was present in 12.5% of Sinopharm vaccinees. One  
99 Covishield/AstraZeneca vaccinee was NP positive, presumably because of infection.  
100 Only Sinopharm contains NP. Three of four subjects (75%) who received two  
101 Sinopharm doses followed by one Pfizer/BioNTech dose were spike-positive (Table 1)  
102 (Supplemental Figure 1). More subjects had NAb to WA strain after Pfizer/BioNTech  
103 (79.7%), and Covishield/AstraZeneca (50.0%), than after Sputnik V (25.0%) or  
104 Sinopharm (20.8%). Neutralizing antibodies to Delta variants were present in fewer  
105 subjects after Pfizer/BioNTech (29.2%), Sputnik V (8.33%), and Sinopharm (12.5%).  
106 NAb to Delta variants were detected in nine subjects after Covishield/AZN (37.50%);  
107 however, 3/9 were NCP ELISA-positive indicating previous SARS-CoV-2 exposure.  
108 Eliminating these three subjects would decrease the percentage with NAb to Delta to  
109 25%. Three of four vaccinees who received a single dose of Pfizer/BioNTech after two  
110 doses of Sinopharm had NAb to WA; one had NAb to Delta.

111

## 112 Discussion

113 Our findings provide additional support for ordinal hierarchy of protection amongst  
114 vaccine platforms, with mRNA vaccines performing better than adenovirus-vectored or  
115 killed virus vaccines [3]. They also confirm that current vaccines, based on the  
116 prototypic WA strain, elicit only minimal levels of NAb to current circulating strains [4 5].  
117 The case surge in Mongolia in June 2021 did not reflect the introduction of the Delta  
118 variant but premature relaxation of physical distancing and masking. These findings  
119 underscore the importance of continuous surveillance for virus evolution, coordinated  
120 modification of vaccines, and a cautious approach to the elimination of classical social  
121 controls for mitigating contagion.

122

## 123 Limitations

124 Our study was limited in numbers and in its retrospective collection of specimens.

125

## 126 Figure Legend:

127

128 **Figure 1. A]** Time line of COVID-19 in Mongolia February 2020 - July 2021; **B]**  
129 Illustration of daily new cases in Mongolia with 3 days and seven days moving average  
130 of daily new cases (blue plot lines) Source:

131 <https://www.worldometers.info/coronavirus/country/mongolia/>

132

133 **Table 1:** SARS-CoV-2 immunoreactivity of plasma samples from 100 healthy  
134 vaccinated individuals as determined by S-ELISA, NCP-ELISA, and end point absolute  
135 viral neutralization assay against WA strain and Delta variant. Samples were collected  
136 with informed consent under the auspices of Onom IRB 241 and IRB 242.

137

138 **Article Information**

139 **Corresponding Authors:** Nischay Mishra, PhD, ND Dashdorj, and W. Ian Lipkin, MD

140  
141 **Author Contributions:** Dr. Mishra & Dr. Lipkin had full access to all of the data in the  
142 study and takes responsibility for the integrity of the data and the accuracy of the data  
143 analysis.

144  
145 Concept and design: Mishra, Lipkin, Danzig, Nara Dashdorj, and ND Dashdorj

146  
147 Acquisition, analysis, or interpretation of data: All authors.

148  
149 Drafting of the manuscript: Mishra, Lipkin

150  
151 Critical revision of the manuscript for important intellectual content: All authors.

152  
153 Statistical analysis: Mishra, Lipkin

154  
155 Obtained funding: Lipkin

156  
157 Administrative, technical, or material support: Mishra, Lipkin, Nara Dashdorj, and ND  
158 Dashdorj

159  
160 Supervision: Mishra, Briese, Lipkin

161  
162 **Conflict of Interest Disclosures:** None


163  
164 **Funding/Support:** This study was funded by the Skoll Foundation and the Onom  
165 Foundation.

166  
167 **Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the  
168 study; collection, management, analysis, and interpretation of the data; preparation,  
169 review, or approval of the manuscript; and decision to submit the manuscript for  
170 publication.

171  
172 **Additional Contributions:** Nancy Messonnier; MD (Skoll Foundation) and Larry  
173 Brilliant; MD(Pandefense) provided insights into study design. We are grateful to CII  
174 staff members; Komal Jain; MS for bioinformatics analyses, Lokendra Chauhan;MS and  
175 Eliza Choi;MS for neutralization assays, Riddhi Thakkar;BS for ELISA assays, James  
176 Ng;BS for RNA extractions and qPCRs, Alexandra Oleynik Petrosov; MS and Alper  
177 Gokden; MS for high throughput sequencing, and Pryanka Sharma;MS for sample  
178 shipment and logistics. We would like to thank Sumiya Byambabaatar; MS, Purevjargal  
179 Bat-Ulzii, Anir Enkhbat, Enkhтуул Batbold, Delgersaikhan Zulkhuu, Byambasuren  
180 Ochirsum, Tungalag Khurelsukh, Ganbold Dalantai, Natsagdorj Burged, Uurtsaikh  
181 Baatarsuren, Nomin Ariungerel, Odgerel Oidovsambuu, Andreas S. Bungert, Zulkhuu  
182 Genden, Dahgwahdorj Yagaanbuyant, and Altankhuu Mordorj for sample collection and  
183 administrative support.

184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202

1. Abdalhamid B, Iwen PC, Wiley MR, Pratt CB, Hinrichs SH. Genome Analysis for Sequence Variants in SARS-CoV-2 Among Asymptomatic Individuals in a Long-term Care Facility. *JAMA Netw Open* 2021;**4**(4):e217939 doi: 10.1001/jamanetworkopen.2021.7939[published Online First: Epub Date] | .
2. Eckhardt CM, Cummings MJ, Rajagopalan KN, et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. *Trials* 2020;**21**(1):499 doi: 10.1186/s13063-020-04422-y[published Online First: Epub Date] | .
3. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. *JAMA* 2021;**325**(13):1318-20 doi: 10.1001/jama.2021.3199[published Online First: Epub Date] | .
4. Tada T, Zhou H, Samanovic MI, et al. Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants. *bioRxiv* 2021 doi: 10.1101/2021.07.19.452771[published Online First: Epub Date] | .
5. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med* 2021 doi: 10.1056/NEJMoa2108891[published Online First: Epub Date] | .



Serological assay	Status	Pfizer/BioNTech (n=24)	Covishield/AZN (n=24)	Sputnik V (n=24)	Sinopharm (n=24)	Sinopharm + Pfiz/BioN* (n=4)	chi-square test significant (<0.05) p values (total positive vs negative)
Spike ELISA	Negative	0 (0.00%)	5 (20.83%)	12 (50%)	17 (70.83%)	0 (0.00%)	Pfizer/BioNTech vs Sputnik V=0.0002, Pfizer/BioNTech vs Sinopharm=0.0001, Covishield/AZN vs Sputnik V=0.03, Covishield/AZN vs Sinopharm=0.0005
	Total positive	24 (100.00)	19 (79.17%)	12 (50%)	7 (29.17%)	4 (100%)	
	Weak positive	2 (8.33%)	2 (8.33%)	5 (20.83%)	4 (16.67%)	1 (25.00%)	
	Positive	22 (91.67%)	17 (70.83%)	7 (29.17%)	3 (12.5%)	3 (75.00%)	
NCP ELISA	Negative	23 (95.83%)	21 (87.50%)	23 (95.83%)	21 (87.5%)	3 (75.00%)	NA
	Total positive	1 (4.17%)	3 (12.50%)	1 (4.17%)	3 (12.5%)	1 (25.00%)	
	Weak positive	1 (4.17%)	2 (8.33%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	
	Positive	0 (0.00%)	1 (4.17%)	1 (4.17%)	3 (12.5%)	1 (25.00%)	
Neutralizing Ab (WA)	Not detected	5 (20.83%)	12 (50.0%)	18 (75.00%)	19 (79.17%)	1 (25.00%)	Pfizer/BioNTech vs Covishield/AZN=0.03, Pfizer/BioNTech vs Sputnik V=0.0002, Pfizer/BioNTech vs Sinopharm=0.00005, Covishield/AZN vs Sinopharm=0.03
	Detected	19 (79.17%)	12 (50.0%)	6 (25.00%)	5 (20.83%)	3 (75.00%)	
	≤1:40	14 (58.30%)	4 (16.70%)	4 (16.70%)	2 (8.33%)	2 (50.00%)	
	≥1:40	5 (20.83%)	8 (33.30%)	2 (8.33%)	3 (12.50%)	1 (25.00%)	
Neutralizing Ab (Delta)	Not detected	17 (70.83%)	15 (62.50%)	22 (91.6%)	21 (87.5%)	3 (75.00%)	Covishield/AZN vs Sputnik V=0.016, Covishield/AZN vs Sinopharm=0.045
	Detected	7 (29.17%)	9 (37.50%)	2 (8.33%)	3 (12.5%)	1 (25.00%)	
	≤1:40	4 (16.67%)	3 (12.50%)	1 (4.20%)	2 (8.33%)	0 (0.00%)	
	≥1:40	3 (12.50%)	6 (25.00%)	1 (4.20%)	1 (4.20%)	1 (25.00%)	

\*Sinopharm + Pfiz/BioN group was not included in statistical analysis due to small sample size. NA- No significant (<0.05) p value was recorded for NCP ELISA.

Table 1: SARS-CoV-2 immunoreactivity of plasma samples from 100 healthy vaccinated individuals; as determined by S-ELISA, NCP-ELISA, and end point absolute viral neutralization assay against WA strain and Delta variant. Samples were collected with informed consent under the auspices of Onom IRB 241 and IRB 242.